GlassScriptPhysician profile
Susan W Choi
NPI 1003880055
$5,190.64
in general payments reported to CMS, 2019-2025
16 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $342 · 2021: $691 · 2022: $1,279 · 2023: $889 · 2024: $1,093 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,259.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,253.25 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $990.36 | 2019-2024 | Farxiga, Airsupra |
| Novo Nordisk INC | $898.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $408.49 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $273.49 | 2019-2022 | |
| Abbott Laboratories | $219.21 | 2022-2025 | Freestyle Libre 3 |
| Allergan, INC. | $217.52 | 2019-2020 | |
| Lilly USA, LLC | $179.60 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.87 | 2020-2023 | Spiriva Respimat |
| Merck Sharp & Dohme LLC | $125.02 | 2019-2023 | Verquvo |
| Exact Sciences Corporation | $113.71 | 2023-2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $109.12 | 2020-2024 | Eliquis, Camzyos |
| Glaxosmithkline, LLC. | $70.21 | 2019-2022 | |
| Philips North America LLC | $69.53 | 2023-2024 | (5044) Mcot |
| Amgen INC. | $63.28 | 2022-2024 | Repatha, Otezla |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $52.46 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.